Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile derma...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

BeachExecutive Jun. 9 at 1:15 AM

$RNAC what is up with the CVR’s? I have 500 of them but will I get anything for them? Tired or staring at them with zero value lol

1 · Reply

Stockswingalert Jun. 9 at 12:20 AM

$RNAC 👀

0 · Reply

kimgysen Jun. 6 at 2:20 PM

$RNAC 🤪🤪🤪

1 · Reply

doDD22 Jun. 5 at 4:58 PM

$RNAC $6 was a premarket recent low Have a feeling they are testing I’ll jump in again if that holds This thing has been beaten to the ground with no news really

2 · Reply

kimgysen Jun. 2 at 5:50 PM

$RNAC 🤪

1 · Reply

kimgysen May. 30 at 6:32 PM

$RNAC 10 refused. Didn't hold after all.

0 · Reply

4976f2e May. 30 at 1:39 PM

$RNAC https://www.nasdaq.com/articles/cartesian-therapeutics-initiates-phase-3-aurora-trial-descartes-08-myasthenia-gravis

0 · Reply

jdlman May. 30 at 11:53 AM

$RNAC let her roll

2 · Reply

Goodstockday May. 29 at 8:03 PM

$RNAC Nice gain today! Time for steady upward movement.

0 · Reply

kimgysen May. 29 at 8:00 PM

$RNAC huh what did I miss lol

0 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grants

May 30, 2025, 7:00 AM EDT - 17 days ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 5 weeks ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 2 months ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 2 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 7:05 AM EST - 3 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Feb 18, 2025, 7:00 AM EST - 4 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Jan 27, 2025, 7:00 AM EST - 5 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 6 months ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 7 months ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 10, 2024, 12:26 PM EST - 7 months ago

Cartesian Therapeutics: Uncertainty Remains

Oct 15, 2024, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 17, 2024, 9:45 AM EDT - 9 months ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 3, 2024, 7:00 AM EDT - 10 months ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 12:55 PM EDT - 1 year ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

BeachExecutive Jun. 9 at 1:15 AM

$RNAC what is up with the CVR’s? I have 500 of them but will I get anything for them? Tired or staring at them with zero value lol

1 · Reply

Stockswingalert Jun. 9 at 12:20 AM

$RNAC 👀

0 · Reply

kimgysen Jun. 6 at 2:20 PM

$RNAC 🤪🤪🤪

1 · Reply

doDD22 Jun. 5 at 4:58 PM

$RNAC $6 was a premarket recent low Have a feeling they are testing I’ll jump in again if that holds This thing has been beaten to the ground with no news really

2 · Reply

kimgysen Jun. 2 at 5:50 PM

$RNAC 🤪

1 · Reply

kimgysen May. 30 at 6:32 PM

$RNAC 10 refused. Didn't hold after all.

0 · Reply

4976f2e May. 30 at 1:39 PM

$RNAC https://www.nasdaq.com/articles/cartesian-therapeutics-initiates-phase-3-aurora-trial-descartes-08-myasthenia-gravis

0 · Reply

jdlman May. 30 at 11:53 AM

$RNAC let her roll

2 · Reply

Goodstockday May. 29 at 8:03 PM

$RNAC Nice gain today! Time for steady upward movement.

0 · Reply

kimgysen May. 29 at 8:00 PM

$RNAC huh what did I miss lol

0 · Reply

kimgysen May. 29 at 5:00 PM

$RNAC Yawn... didn't hold 10

0 · Reply

EmbryonicJourney May. 27 at 7:43 PM

$RNAC Are you f**cking kidding me - what a joke. I've been in SELB/RNAC 5 years now and nothing but red to show for it despite averaging down. I wouldn't feel so bad if the company was performing poorly but this isn't the case

1 · Reply

abcdzepeda May. 22 at 7:33 PM

$RNAC if, the stock price does not jump quite a bit once Trump‘s big beautiful bill passes in July. I may consider selling this ticker!

3 · Reply

kimgysen May. 21 at 6:17 PM

$RNAC F* trials. All this thing does is half.

0 · Reply

Goodstockday May. 21 at 4:06 PM

$RNAC Phase 3 clinical trial just opened!

1 · Reply

CharlieMungersghost May. 16 at 2:32 PM

$RNAC what's errbodies averages? What's your price targets ??

3 · Reply

CharlieMungersghost May. 16 at 2:32 PM

$RNAC come on fellas Let's get a bid on this Tim springer is smarter than yee

0 · Reply

Jutski_bipolar May. 14 at 9:55 AM

$RNAC bid it simps

0 · Reply

kimgysen May. 13 at 4:52 PM

$RNAC Tim your stock is turning into smashed potato

0 · Reply

Armonica423 May. 10 at 5:41 PM

$RNAC Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

kimgysen May. 9 at 4:58 PM

$RNAC This is what the stock looks like, you couldn't tell where is the RS lol

0 · Reply

InjureReserve May. 9 at 12:35 PM

$RNAC when will they raise cash? 182m is about where selecta was before they pulled the trigger to dilute, with this close to breaking into single digit stock price and market cap of 280m, have to assume they are watching this closely and don’t want to wait too long to do it just in case

0 · Reply

Market Cap	270.44M
Revenue (ttm)	38.91M
Net Income (ttm)	-77.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-198.97%
Debt to Equity Ratio	0.00

Volume	20,504
Avg Vol	92,406
Day's Range	N/A - N/A
Shares Out	25.95M
Stochastic %K	57%
Beta	0.33
Analysts	Strong Sell
Price Target	$36.17